This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
“Our next question will come from Andrew Baum with Citi.” | Citi analyst Andrew Baum, after covering Pfizer for more than a decade, will join the Big Pharmacompany as chief strategy and innovation officer. In the role, he'll oversee the drugmaker's portfolio management and businessdevelopment activities.
Thomas Kassberg, Chief Business Officer, Ultragenyx. Thomas Kassberg, Chief Business Officer, Ultragenyx. I think you really need to get the feedback directly from patients and then incorporate that feedback as you think about how you’re going to develop the product to be successful. Tom Kassberg, Ultragenyx. Dan Curran, Takeda.
Streamlined development, flexibility in manufacturing, and improved product quality at reduced costs, while gaining access to capabilities and capacity are some of the factors fuelling the pharmaceutical solid dosage contract manufacturing market.
to develop an intra-uterine sensor system and generate clinical data that could be used for European approval. The Future Fund participated in the second tranche of the fundraising alongside other investors, unlocking matched financing and helping to drive the business forward towards commercialisation.
Across the industry, pharmacompanies are turning to AI and real-world data to address many of the challenges of running clinical trials. His research focuses on the development of big data machine learning for tracking the health of complex systems. But what does it take to implement these innovations?
.” It also said that “strategic businessdevelopment” is a top priority for the company at the moment, reflecting a longstanding concern that it has become over-reliant on Keytruda and needs to diversify.
For the past year, life science companies around the world worked at breakneck speed to develop and manufacture safe and effective treatments to respond to the COVID-19 pandemic. India and China have seen the emergence of strong, local pharmacompanies. The right answer requires upfront analysis.
Aaron Gani, founder and CEO of BehaVR, and Krys Zaluski, director of businessdevelopment, digital health at Sumitomo Dainippon Pharma, discuss their groundbreaking partnership to develop and commercialise digital therapeutics (DTx) products. . “Our capabilities are very complimentary.
As moderator Gareth Powell – businessdevelopment officer, patient engagement and clinical development service project lead at the NIHR – noted, the Institute has seen fantastic feedback from patients on the increased use of virtual engagement over the course of pandemic.
Pharmacompanies face many challenges when involving patients in the design of clinical trials – but doing so can have huge benefits further down the line, improving the sustainability and quality of research. He said that this can be used to shape trials to make them easier for patients, with potential benefits in terms of adherence.
This is expected to create immense problems across developing countries with the likely exception of India and China. However, some of the pharmacompanies fared relatively well. Especially big Pharma players, such as Amgen, Pfizer, and BMS demonstrated high single-digit growth in sales during the recession.
The legacy of this disruption has been a rethink in the way pharmacompanies do business. The pharma supply chain is emerging strongest and most sustainable where there is a high level of automation and digitalization. Visibility that’s not accessible in real time isn’t really visibility at all.
One is the platform, which is essentially what our internal solution developers capitalise on, and then we externalise that capability to third-party developers.”. External developers can use Komodo’s platform and build analytics modules to explore other use cases using low code or no-code environments. The business of data.
This includes using its technology as a ‘ digital excellence cloud ’ to harness data, content management, insights and execution while also offering business consulting services to help pharmacompanies with strategy, processes, and change management.
Gaurav Kapoor, co-founder and executive vice president of Indegene, tells pharmaphorum how pharma can take lessons from the entertainment industry and prepare for the Metaverse to enhance content engagement. Pharmacompanies’ customer communication methods require reimagining as technology progresses.
Pharmacompanies will need to continually rethink what works and not be afraid to experiment with solutions they’ve never tried before. This trend can be seen as a net positive, in that it will enable digital therapeutic solution developers to concentrate on building the individual vertical products that will live on these platforms.
Healthcare technology firm Seqster has introduced a new version of its service that aims to help pharmacompanies work with patients’ data while on virtual clinical trials. Seqster announced the new version of its platform had been launched on the Microsoft Azure cloud at the annual JP Morgan Healthcare Conference. The new Seqster 7.1
Smith shared this approach, remarking that 4BIO Capital takes a collaborative approach to invest, working closely with the founders and companies to develop a shared vision for growth. But he noted getting the right people on the right path to success allows companies to create a more impactful story to put to investors.
With an average of only 5 – 10 projects awarded to EU companies by the FDA each year, this development represents a landmark achievement for RCPE and reflects the potential impact of these projects within the global pharma industry. Website: [link]
Facebook: [link]
Twitter: [link]
YouTube: [link]. # # #.
Ties Kroezen, venture leader of Community Life Centers and businessdevelopment manager for Philips Africa, tells us about the challenges present within the African healthcare system, solutions the companydeveloped to help patients and providers connect, and how pharma can assist with delivering better care to African residents.
In the very beginning, it becomes a necessity for a Business Consultant to have appropriate knowledge about their client’s business. So discovering and learning about the company as a whole becomes essential. Apart from identifying problems, the next step for a business consultant is to develop solutions to problems.
Pharma Consultant. From discovery to development and production of any biological product, aid in decision making is given by Pharma Consultants. Pharma Consultancy Modus Operandi. A pharmaceutical consultant provides companies with expert advice on pharmaceutical development and sales.
Kurtz brings more than 26 years of experience in global manufacturing, engineering, supply chain, CMC development and program management for drugs and devices at various stages of development. Cadavid will be responsible for the strategy, direction and execution of the company’s clinical development programs.
Many companies realise traditional clinical trial processes need modification to improve efficiency, and partnerships are forming in distinct ways to evaluate how digital therapeutics, such as VR can enhance trial designs and outcomes. He oversees operations, including businessdevelopment, sales and marketing, and people.
It’s not uncommon to find that two pharmacompanies of similar size and scope, headquartered in the same country, will have different interpretations of legal and regulatory facets. BusinessDevelopment Account Manager. What is your corporate compliance policy? All towards the goal of “zero-risk”! Robert Hollands.
Here, we will deep-dive into the top five fastest growing pharma and biotech companies in 2024, showcasing their innovative strategies and inspiring achievements. Pfizer (Overall Rank 268) Leading the list is one of the most renowned pharmacompanies in the world: Pfizer. Vertex is growing at a CAGR of 28.97
And although academia and industry have often been pitted against each other in the realm of scientific discovery and development, there may be more similarities and synergies between the two than we may think. WeiQi Lin, MD, PhD, executive vice president of research & development and principal scientist, DURECT Corporation.
Pharmacompanies and world health stand to benefit from new technologies, but it’s a tough time to be an investor – and an even tougher one for firms seeking investment. From close to zero, central bank interest rates have risen to 3% in the Eurozone, 4% in the UK and nearly 5% in the USA.
Africa has considerable advantages and opportunities for trialling investigational medicinal products that, if pharmacompanies can correctly harness, will turn the continent into a superpower for clinical trials. The average representation of other ethnic groups in the US is very low, with 7.3% being African American, 3.4%
Big data analysis can be enormously powerful in providing insights for business strategy throughout the pharma value chain, including in the acceleration of drug discovery and development, optimization of manufacturing processes, management of supply chains and the creation of innovative sales and marketing strategies.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content